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Introduction: Severe lung injury is triggered by both the SARS-CoV-2 infection and the
subsequent host-immune response in some COVID-19 patients.
Methods: We conducted a randomized, single-center, open-label, phase II trial with the
aim to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus
standard of care (SoC) vs. SoC alone, in hospitalized patients with severe COVID-19.
The primary outcome was time to clinical stability within 56 days after randomization.
Results: From April 1 to May 2, 2020, 55 patients were prospectively included for
subsequent randomization; 27 were assigned to the experimental group and 28 to the
control group. The experimental treatment was not associated with a difference in time
to clinical stability (hazard ratio 0.73 [95% CI 0.39–1.37]) nor most secondary outcomes.
Median methylprednisolone cumulative doses were significantly lower (360mg [IQR 360–
842] vs. 870mg [IQR 364–1451]; p= 0.007), and administered for a shorter time (median
of 4.00 days [3.00–17.5] vs. 18.5 days [3.00–53.2]; p = 0.011) in the experimental
group than in the control group. Although not statistically significant, those receiving the
experimental therapy showed a numerically lower all-cause mortality than those receiving
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SoC, especially at day 10 [2 (7.41%) vs. 5 (17.9%); OR 0.39 (95% CI 0.05–2.1);
p = 0.282]. The total number of non-serious adverse events was 42 in each the
two groups. Those receiving experimental treatment had a numerically higher rate of
non-serious infectious adverse events [16 (38%) vs. 10 (24%)] and serious infectious
adverse events [7 (35%) vs. 3 (23%)] than those receiving SoC.
Conclusions: The combined use of methylprednisolone pulses plus tacrolimus, in
addition to the SoC, did not significantly improve the time to clinical stability or other
secondary outcomes compared with the SoC alone in severe COVID-19. Although not
statistically significant, patients receiving the experimental therapy had numerically lower
all-cause mortality than those receiving SoC, supporting recent non-randomized studies
with calcineurin inhibitors. It is noteworthy that the present trial had a limited sample
size and several other limitations. Therefore, further RCTs should be done to assess the
efficacy and safety of tacrolimus to tackle the inflammatory stages of COVID-19.
Clinical Trial Registration: Identifier [NCT04341038/EudraCT: 2020-001445-39].
Keywords: COVID-19, SARS-CoV-2, methylprednisolone, tacrolimus, inflammation, lung injury
INTRODUCTION
In December 2019, a new type of human coronavirus (SARS-
CoV-2), causing an emerging diseases (COVID-19), was first
recognized in China and spread globally (1, 2). The COVID-
19 was declared a pandemic by the WHO on March 12, 2020
(3), and it continues to spread worldwide, causing considerable
morbimortality and economic damage.
SARS-CoV-2 has evolved some mechanisms to disturb host-
immune response. In fact, impaired interferon (IFN) signature
in early stages leads to a persistent blood viral load and a
later hyper-inflammatory response that has been related with
a worse COVID-19 outcome (4, 5). Accordingly, antiviral
followed by anti-inflammatory drugs have been recommended
(6). While some immunosuppressive treatments could be
potentially harmful, others have been suggested for treating the
disproportionate inflammation triggered by the SARS-CoV-2
infection (7).
When the TACROVID trial was designed in March 2020, data
from the main COVID-19 randomized controlled trials (RCT)
(8–10) were still not available and there were no therapies for
treating the COVID-19 illness other than supportive care. Due
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; ARDS,
acute respiratory disease syndrome; HUB, Hospital Universitari de Bellvitge;
CNIs, calcineurin inhibitors; CoV, Coronavirus; COVID-19, Coronavirus disease
2019; CRP, C-reactive protein; CXCL, chemokine (C-X-C motif) ligand; CXR,
chest x-ray; ECMO, extracorporeal membrane oxygenation; eCRF, electronic
case report form; FiO2, fractional inspired oxygen; G-CSF, granulocyte colony-
stimulating factor; GFR, glomerular filtration rate; ICF, informed consent
form; IFN, interferon; IL,interleukin; ITT, intention to treat; LDH, lactate
dehydrogenase; MCP, monocyte chemoattractant protein; PaO2, arterial oxygen
partial pressure; RCT, randomized controlled trial; RT-PCR, reverse transcription
polymerase chain reaction; SAE, serious adverse event; SARS-CoV, Severe Acute
Respiratory Syndrome Coronavirus; SARS-CoV-2, Severe Acute Respiratory
Syndrome Coronavirus 2; SF,SpO2/FiO2 ratio; SoC, Standard of Care; SOFA score,
Sequential Organ Failure Assessment Score; SpO2, oxygen saturation; TNF, tumor
necrosis factor.
to the lack of evidence-based treatments, a large number of
patients received off-label and compassionate therapies, based
on their in vitro antiviral or immunomodulatory properties. The
repurposing of older drugs was the initial main strategy given
their proven safety profile (11). Today, RCTs are still needed in
order to provide evidence-based effective and safe therapies for
COVID-19 management (12).
Our hypothesis was that methylprednisolone pulses plus
tacrolimus could be an effective and safe drug combination
for severe COVID-19 patients. Accordingly, given the health
emergency due to the rapid spread of SARS-CoV-2 worldwide,
we conducted a proof-of-concept study in a randomized,
single-center, open-label clinical trial with the aim to evaluate
the efficacy and safety of methylprednisolone pulses and
tacrolimus plus standard of care (SoC), vs. SoC alone, in
severe COVID-19 patients with lung injury and systemic
hyperinflammatory syndrome.
The rationale for the current RCT was based on the fact
that corticosteroids, such as methylprednisolone, are a pillar in
the treatment of multiple inflammatory diseases, with several
mechanisms of action impacting both the innate and adaptive
arms of immunity. Regarding tacrolimus, the reason for its use
was based on both the anti-inflammatory and anti-viral actions
of calcineurin inhibitors (CNIs). As an immunomodulatory
agent, tacrolimus impairs lymphocyte function and consequently
decreases in pro-inflammatory cytokines (7, 13). In this respect,
severe COVID-19 disease presents a similar clinical and cytokine
profile to other disorders like secondary hemophagocytic
lymphohistiocytosis (14), where CNIs play a central role in
its treatment (15). Additionally, several human coronavirus
replication depends on immunophilin pathways, which can be
inhibited by CNIs in cell culture (16, 17). Based on these two
mechanisms, it has been suggested that CNIs could be used to
treat COVID-19 (18). In fact, recent non-randomized studies
suggest that cyclosporine could reduce mortality, mainly in
patients with moderate to severe COVID-19 (19, 20). Our study
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is the first RCT assessing the effect of corticosteroids plus a
CNI (tacrolimus) in hospitalized patients with severe COVID-
19. They are low-cost drugs with a well-known safety profile




TACROVID was a pragmatic, randomized (1:1) with parallel-
groups, open-label, single-center, phase II clinical trial to
evaluate the efficacy and safety of methylprednisolone pulses and
tacrolimus plus SoC, vs. SoC alone, in severe COVID-19 patients
with lung injury and systemic hyperinflammatory syndrome.
The TACROVID trial was conducted at Hospital Universitari
de Bellvitge (HUB), a 750-bed tertiary care public hospital for
adults in Barcelona (Catalonia, Spain). HUB is the reference
hospital for high complexity patients from the southern area of
Catalonia, a region of∼2 million inhabitants.
In March 2020, the HUB’s Ethical Committee for Drug
Research and the Spanish Agency for Drugs and Health Products
approved the protocol and informed consent form (ICF). This
trial complies with the Declaration of Helsinki and Good Clinical
Practice guidelines, and personal data protection as required by
Spanish law (LOPD 3/2018). The trial registration numbers are
NCT04341038 and EudraCT 2020-001445-39. All patients (or a
legal representative if patients were unable) had to provide ICF
prior to initiation of the trial procedures. The protocol is available
online (21).
Population
Patients were included in the trial if they met all the inclusion
criteria and none of the exclusion criteria. Inclusion criteria: (1)
COVID-19 infection confirmed by nasopharyngeal RT-PCR; (2)
New pulmonary infiltrates (either by chest X-ray or computerized
axial tomography); (3) Respiratory failure defined by PaO2/FiO2
< 300 or SpO2/FiO2 < 220; (4) High analytical inflammatory
parameters: CRP > 100 mg/L, and/or D-Dimer > 1,000 µg/L,
and/or Ferritin > 1,000 µg/L. Exclusion criteria: (1) Critically
ill patients with life expectancy ≤ 24 h; (2) Glomerular filtration
≤ 30 ml/min/1.73m2; (3) Leukopenia ≤ 4,000 cells/µl or other
conditions that cause immunosuppression; (4) Concomitant
potentially serious infections; (5) Contraindication for the use
of corticosteroids or tacrolimus according to the Summary of
Product Characteristics; (6) Known hypersensitivity to any of
the study drugs, their metabolites, or formulation excipient; (7)
Previous participation in a RCT in the last 3 months.
Randomization
After obtaining the ICF, patients were randomized using
the RedCap, a secure web application for building and
managing electronic case report forms (eCRF). Patients were
randomly (1:1) assigned to one of the following arms with no
baseline stratification:
1. Experimental arm: methylprednisolone pulses of 120
mg/day had to be administered on 3 consecutive days
after randomization (if not previously administered).
The administration of higher doses or longer duration
of corticosteroids was allowed if their treating physicians
considered it appropriate. Tacrolimus starting dose was 0.05
mg/kg (Adoport R©) twice daily. Patients using lopinavir-
ritonavir received 0.2mg (Modigraf R©) every 48 h. Thereafter,
tacrolimus dosing was individualized through therapeutic
drug monitoring to achieve blood trough levels of 8–10 ng/ml.
In addition, patients in the experimental arm could receive
standard of care (SoC) for their management in accordance
with treating physicians.
2. Control arm (SoC): SoC included measures of supplemental
oxygen and respiratory support, fluid therapy, antipyretic
treatment, postural measures, low molecular weight
heparins, and could also include treatments with unproved
antiviral (lopinavir-ritonavir, hydroxichloroquine, etc.)
or immunosuppressive (any regimen of corticosteroids,
tocilizumab, anakinra, etc.) drugs, or those necessary at the
discretion of the treating physician, except for cyclosporine
and/or tacrolimus.
The experimental drugs were started immediately after the
participants were randomly assigned to that group. The
experimental treatment was discontinued after patients achieved
clinical stability, which was defined in the outcomes section.
Experimental treatment was also discontinued if the included
patient presented a severe or potentially severe infection,
required invasive mechanical ventilation, extracorporeal
membrane oxygenation (ECMO), or had any seriousmedication-
related adverse event (of special interest refractory high blood
pressure, decrease of more than 50% in the GFR compared with
the baseline, or ventricular tachycardia).
Procedures
All patients were followed from day 0 through day 56 or
death. The planned visits and procedures are detailed in the
TACROVID trial protocol (Supplementary Table 1) (21). Follow
up visits were face-to-face to evaluate disease outcomes, and
data was collected using an eCRF. The Bellvitge Biomedical
Research Institute (IDIBELL) Clinical Research and Clinical
Trials Unit (UICEC-IDIBELL) carried out the monitoring of the
trial. Regular monitoring was performed by the UICEC-IDIBELL
according to the International Conference on Harmonization
(ICH) good clinical practice (GCP) requirements. The UICEC-
IDIBELL carried out pharmacovigilance of the trial.
Outcomes
The primary outcome was time (days) to clinical stability within
56 days after randomization. Clinical stability was defined as
fulfilling all of the following criteria for 48 consecutive hours:
body temperature≤ 37.5◦C; PaO2/FiO2 > 400 and/or SpO2/FiO2
> 300; and respiratory rate ≤ 24 rpm. Treatment failures were
defined as: (1) patients that did not meet criteria for clinical
stability 56 days after starting treatment; (2) patients presenting
a serious adverse event attributed to the experimental treatment;
or (3) patients dying after being included in the clinical trial.
The secondary outcomes included the number of days until
normalization of each of the clinical and analytic parameters
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from day 0 through day 56; the clinical status according to
the eight-point ordinal scale (22) from day 0 through day
56; patients who achieved a clinical status ≤ 3 after 10
days or hospital discharge (whichever was first), and on days
28 and 56; patients who achieved clinical stability after 10
days or hospital discharge (whichever was first), and on days
28 and 56; value of each of the analytical parameters after
10 days or hospital discharge (whichever was first), and on
days 28 and 56; number of days receiving trial experimental
treatment; days until hospital discharge; number of patients and
days requiring non-invasive and invasive ventilatory support
devices during hospitalization; changes in blood quantitative
viral load by RT-PCR before start of treatment and during
follow up; changes in expanded cytokine profile before starting
treatment and on days 14, 28, and 56; pulmonary parenchyma
involvement using chest x-ray (CXR) pulmonary severity score
(23) at baseline, and at day 56; adverse events according
to their seriousness and relationship to trial experimental
treatment; COVID-19 related mortality at day 28 and 56
after randomization; all-cause mortality at day 28 and 56
after randomization.
Statistical Analysis
The intention-to-treat (ITT) population consisted of all
randomized patients. We estimated that the assignment of 42
patients with 1:1 randomization would provide at least 80%
power to reject the null hypothesis that the experimental and
control survival curves are equal. The hazard ratio of clinical
stability of control patients in relation to the patients in the
experimental group was 0.52, and a median survival time in
the control group of 16 days was assumed. The probability of
Type I error associated with this hypothesis test was 0.05 and 5%
withdrawal was anticipated.
A descriptive analysis of the baseline profile of patients
included in the ITT population was carried out. The primary
efficacy outcome was time (days) to clinical stability within 56
days after randomization, and was estimated using the Kaplan–
Meier method, and cumulative incidence curves were compared
between the two groups with the log-rank test. The stratified
Cox proportional-hazards model was used to estimate the hazard
ratio (for experimental group as compared with control) and
95% confidence interval. The main analysis was repeated on each
clinical stability criterion.Moreover, odds of clinical stability were
compared at 10, 28, and 56 days using a logistic regression.
Time to WHO eight-point ordinal scale ≤ 3 and time to
death (secondary outcomes) were compared between the two
groups using the Kaplan–Meier approach, and using a logistic
regression at 10, 28, and 56 days. A sensitivity analysis of the time
to hospital discharge was performed. Safety was assessed in all
patients; patients were grouped according to the study group. A
safety review was performed by the UICEC-IDIBELL.
The IDIBELL Biostatistical Unit performed the analysis and
analysts were blinded to the treatment received by patients
(intervention vs. usual care). R version 4.0.3 for Windows (R
Foundation for Statistical Computing, http://www.r-project.org)
was used for data management and analysis.
RESULTS
Fifty-five patients were prospectively included from April 1,
2020 to May 2, 2020 in the trial for subsequent randomization.
Twenty-seven were assigned to the experimental group and 28
to the control group (ITT and safety population) (Figure 1). Of
those assigned to the experimental group, 24 (88.9%) patients
received the treatment as assigned. Three patients discontinued
the treatment during the first 5 days and were excluded from the
per-protocol analysis population. Of those assigned to the control
group, 26 (92.9%) were eligible for the per-protocol analysis.
Two deceased patients were excluded owing to a short follow-up
(<5 days).
The mean age of the 55 patients included in the ITT
analysis was 63.2 (SD 13) years; 44 (80%) were male (Table 1).
Overall, 39 (70.9%) of the patients were Caucasian and
16 (29.1%) were Latino. The most common pre-existing
comorbidities were hypertension (43.6%), obesity (43.6%), and
diabetes (27.3%). Thirty-eight (69.1%) patients had no smoking
history. The median Charlson index was 3 in both groups.
Except for one patient in the experimental group, all patients
showed independence in tasks of daily living without cognitive
impairment. There were no patients admitted from long-term
care facilities or nursing homes.
Some imbalances existed at enrollment between the two
groups. The time between symptom onset and randomization
was 11 days (IQR 9–17) in the experimental group compared
to 14 days (IQR 9.75–19.2) in the control group. A higher
proportion of the control group had required high-flow
nasal cannula or non-invasive mechanical ventilation and
corticosteroids. Conversely, the experimental group showed
higher CRP and creatinine kinase. No other major differences
in symptoms, signs, laboratory results, disease severity, or
treatments were observed between the groups at baseline
(Table 1).
Patients in the experimental group received a median
of 9 (IQR 7–11) days of tacrolimus, with a median time
from symptom onset to tacrolimus administration of 11 days
(IQR 9–17). Median tacrolimus dose per kg bodyweight was
0.0375 mg/kg twice daily (IQR 0.0276-0.05), and it was 0.0025
mg/kg every other day (IQR 0.0024-0.0029) when receiving
concomitant lopinavir-ritonavir. Tacrolimus median trough
levels were 8.4 ng/ml (IQR 4.6-15.1). The need for high flow
devices and mechanical ventilation (invasive or not) during the
follow up was similar in the two arms of the trial (Table 2).
All patients received corticosteroids, with a median time from
symptom onset to corticosteroid therapy of 10 days (IQR 8.00–
14.0) in the experimental group and 10 days (IQR 8.75–15.0)
in the control group. The dose of any type of corticosteroid
received from admission to day 56 of the trial was converted to
methylprednisolone, and the cumulative doses were significantly
lower in the experimental group than in the control group
(median methylprednisolone cumulative doses were 360mg
[IQR 360–842] vs. 870mg [IQR 364–1451]; p = 0.007), as
was the duration of corticosteroid treatment (median of 4.00
days [3.00–17.5] vs. 18.5 days [3.00–53.2]; p = 0.011). Most
of the patients included also received tocilizumab (25 [92.6%]
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FIGURE 1 | Trial profile.
in the experimental group vs. 24 [85.7%] in the control
group); p = 0.669). Two patients (7.14%) in the control group
received anakinra. After tacrolimus initiation no patients in the
experimental group received any additional immunosuppressant
drug other than steroids. No significant differences were observed
among the two groups in the number of patients who received
lopinavir-ritonavir, hydroxychloroquine, or antibiotics. Length of
oxygen support, as well as the rate and duration of ventilation
support were not significantly different between the two groups
(Table 2).
The final study follow-up was on June 27, 2020. In the ITT
population, no statistically significant differences were observed
in time to clinical stability within 56 days after randomization
between the two groups (median 10.0 days [IQR 7.0–13.0] in the
experimental group vs. 11.0 days [8.0–18.0] in the SoC group;
HR 0.73 [95% CI 0.39–1.37]; Asymptotic Logrank test p-value
= 0.325) (Table 3 and Figure 2). The times to normalization
of each of the variables that compound clinical stability (body
temperature, PaO2/FiO2 or SpO2/FiO2; and respiratory rate) did
not differ significantly between arms. Results for time to clinical
stability were similar in the per-protocol population (median
10.0 days [IQR 7.00–12.5] in the experimental group vs. 11.0
days [IQR 8.0–18.8] in the SoC group; HR 0.77 [95% CI 0.40–
1.47]; Asymptotic Logrank test p-value = 0.473). At 56 days
after randomization, the number of patients who had achieved
clinical stability, those with an eight-point ordinal scale ≤ 3,
and patients discharged did not differ significantly between the
groups (Table 3).
Although not statistically significant, those receiving the
experimental therapy showed a numerically lower all-cause
mortality than those receiving SoC, especially at day 10 (2 [7.41%]
vs. 5 [17.9%]; OR 0.39 [95% CI 0.05–2.1]; p = 0.282) and at day
28 (4 [14.8%] vs. 6 [21.4%]; OR 0.65 [95% CI 0.14–2.67]; p =
0.551) (Figure 3). Patients in the experimental group died later
at a median of 13 days from randomization (IQR 10.0–26.0),
while in the control group the median was 7 days (3.25–10.0);
but these differences were not statistically significant (logrank test
p-value 0.710). The number of available events by group (four
deaths per study arm) was not enough to get reliable estimators to
analyze the effect of experimental therapy on all-cause mortality
adjusting by age or sex. Similar results were obtained for COVID-
19-related mortality (Table 3) (Supplementary Figure 1).
There were no significant differences in the evolution of
analytic parameters (lymphocytes, CRP, ferritin, LDH, IL-6, D-
dimer) between the two arms (Supplementary Table 2), or in
the expanded cytokine profile (Supplementary Table 3). Serum
cytokine levels at different time points during the trial showed
increased levels of pro-inflammatory cytokines like CXCL10 (IP-
10), IL-6, IL-18, TNF-alpha, and soluble IL-2 receptor alpha;
and regulatory cytokines such as IL-10 and IL-1RA at day 0
and day 14. In both groups, serum cytokine levels tended to
have decreased by day 28 and day 56 (Supplementary Figure 2).
In the same way, there were no significant differences between
groups in pulmonary parenchyma involvement according to
the CXR pulmonary severity score at inclusion or at day 56
(Supplementary Table 4).
All 55 patients were nasopharyngeal and oropharyngeal RT-
PCR positive at diagnosis, but viral load data was available in
24 (88.8%) patients in the experimental group and 20 (71.4%)
in the control group. The median baseline viral load of upper
respiratory tract swabs was 244,954 (IQR 8,566–7,458,132) log10
copies per ml in the experimental group and 388,329 (IQR
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Age (years) 61.5 (13.9) 64.8 (12.1)
Sex (male) 23 (85.2%) 21 (75%)
Race or ethnic group
Caucasian 20 (74.1%) 7 (25%)
Hispanic or Latino 7 (25.9%) 9 (32.1%)
Other 0 (0%) 1 (3.6%)
Coexisting conditions
Smoking history 7 (25.9%) 10 (35.7%)
Hypertension 10 (43.5%) 14 (53.8%)
Diabetes mellitus 6 (22.2%) 9 (32.1%)
Obesity 11 (40.7%) 13 (46.4%)
Coronary heart disease 3 (11.1%) 1 (3.6%)
Charlson Index 3 (1–3) 3 (2–4)
Barthel Index 100 (100–100) 100 (100–100)
Time from symptom onset to
randomization, days
11 (9–17) 14 (9.75–19.3)
Early (≤10 days from symptom
onset)
13 (48.1%) 10 (35.7%)
Late (>10 days from symptom
onset)
14 (51.9%) 18 (64.3%)
Body temperature, ◦C 36.3 (0.5) 36.31 (0.53)









FiO2 0.5 (0.5–0.6) 0.6 (0.6–0.9)
Score on eight-point ordinal scale 5 (5–5) 5 (5–6)
5.Hospitalized, requiring
supplemental oxygen




4 (14.8%) 12 (42.9%)
PSI 77.0 (27.3) 79.4 (23.3)
NEWS 7.5 (2.1) 7.71 (1.88)
SOFA score 1 (0–1) 1 (0–1)
Laboratory
Lymphocyte count, ×109/L 0.72 (0.58–0.91) 0.56 (0.44–0.78)
Platelets count, ×109/L 311 (115) 288 (123)
Serum creatinine, mg/dl 0.84 (0.23) 0.79 (0.24)
ALT, U/L 47.0 (32.0–70.5) 51.5 (35.8–92.2)
AST, U/L 39.0 (30.5–56.0) 41.0 (24.8–67.0)









IL-6, ng/L 86.1 (37.6–785) 80.4 (41.4–667)
Creatinine kinase, U/L 75.0 (43.5–198) 47.5 (31.5–65.0)
D-dimer, µg/L 612 (250–2672.5) 741 (352–2195.5)
Baseline viral load of nasopharyngeal













Lopinavir-ritonavir 23 (85.2%) 22 (78.6%)
Hydroxychloroquine 27 (100%) 28 (100%)
Antibiotic 13 (48.1%) 8 (28.6%)
Corticosteroids 10 (37.0%) 17 (60.7%)
Tocilizumab 24 (88.9%) 22 (78.6%)
Data are median (IQR) or mean (SE), and n (%). ALT, alanine aminotransferase; AST,
aspartate aminotransferase; CRP, C-reactive protein; FiO2, fractional inspired oxygen; IL-
6, interleukin-6; LDH, lactate dehydrogenase; NEWS, National EarlyWarning Score; PaO2,
arterial oxygen partial pressure; PSI, Pneumonia Severity Index; SOFA, Sequential Organ
Failure Assessment; SpO2, oxygen saturation.
22,551–980,683) log10 copies per ml in the control group. During
follow-up, upper respiratory tract viral load decreased over time
similarly in both arms, becoming undetectable at day 28 and
56 in most patients. Blood RT-PCR at baseline was available in
24 (88.8%) patients in the experimental group and 21 (75%)
in the control group. Almost all of them showed undetectable
viral RNA in blood samples at baseline and during follow-up
(Supplementary Table 5 and Supplementary Figure 3).
Adverse events (AE) occurred in 46 (83.6%) patients. Twenty-
two (44%) patients had one AE, five (9.1%) had two AE, 11
(20%) had three AE, and eight (14.5%) had four or more
AE. Sixty-two AE were reported in 23 (85.2%) patients in the
experimental group, 20 of them met the seriousness criteria
(corresponding to nine patients), and nine were assessed as
related to the experimental treatment. In the control group,
55 AE were reported in 23 (82.1%) patients, of which 13
were considered as serious AE (corresponding to 10 patients)
(Supplementary Table 6).
The total number of non-serious AE was 42 in each of
the two groups. Those receiving experimental treatment had
a numerically higher rate of non-serious infectious AE (16
[38%] vs. 10 [24%]), and serious infectious AE (7 [35%] vs.
3 [23%]) than those receiving SoC. In contrast, the control
group showed poorer glucose metabolism and a higher overall
bleeding rate. Five (18.5%) patients in the experimental group
developed special interest AE, these being hypertension in three
(60%) of them and renal impairment in two (40%). Four deaths
in each group were judged by the site investigators to be
related to COVID-19 acute respiratory distress syndrome. One
death reported in the experimental group was attributed to
hemorrhagic stroke, and regarding the two deaths in the control
group, one was attributed to Staphylococcus aureus septicaemia
and the other to hemopericardium (Supplementary Table 6).
DISCUSSION
The TACROVID trial found that methylprednisolone
bolus plus tacrolimus did not significantly improve the
time to clinical stability (primary outcome), mortality or
other secondary outcomes compared with the SoC in
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TABLE 2 | Treatments received during hospitalization and the trial period.
Experimental (N = 27) Control (N = 28) P-value
Duration of oxygen support from randomization, days 11.0 (8.00–19.5) 13.0 (7.75–23.0) 0.953
High-flow or ventilatory support therapies 14 (51.9%) 18 (64.3%) 0.509
HFNC and/or non-invasive mechanical ventilation 13 (48.1%) 18 (64.3%) 0.350
Invasive mechanical ventilation 5 (18.5%) 4 (14.3%) 0.729
ECMO 0 (0%) 1 (%) ··
Duration of high-flow or ventilatory support from randomization, days 8.00 (5.00–27.2) 6.50 (4.25–14.2) 0.303
HFNC and/or non-invasive mechanical ventilation 5.00 (4.00–9.00) 5.00 (3.25–9.00) 0.532
Invasive mechanical ventilation 22.0 (11.0–29.0) 10.00 (4.25–21.5) 0.327
Renal replacement therapy 2 (7.4%) 0 (0%) ··
Corticosteroid therapy 27 (100%) 28 (100%) ··
Duration of corticosteroid therapy, days 4.00 (3.00–17.5) 18.5 (3.00–53.2) 0.011
Methylprednisolone cumulative dose 360 (360–842) 870 (364–1,451) 0.007
Tocilizumab 25 (92.6%) 24 (85.7%) 0.669
Anakinra 0 (0%) 2 (7.14%) 0.491
Lopinavir-ritonavir 23 (85.2%) 22 (78.6%) 0.729
Hydroxychloroquine 27 (100%) 28 (100%) ..
Heparin 27 (100%) 28 (100%) ..
Antibiotics 23 (85.2%) 26 (92.9%) 0.422
Data are n (%) compared using Pearson’s chi-squared test, and median (interquartile range) compared using the Wilcoxon test. ECMO, extracorporeal membrane oxygenation; HFNC,
high-flow nasal cannula.
TABLE 3 | Effect of allocation to experimental group on key study outcomes.
Experimental (N = 27) Control (N = 28) HR/OR [CI 95%] P-value
Time to clinical stability, days 10.0 (7.00–13.0) 11.0 (8.00–18.8) 0.73 [0.39–1.37] 0.327∧
Time to body temperature normalization, days 1.00 (1.00–2.00) 1.00 (1.00–1.00) 0.8 [0.47–1.36] 0.415∧
Time to PaO2/FiO2 > 400 and/or SpO2/FiO2 > 300 9.00 (7.00–11.0) 11.0 (8.00–18.8) 0.81 [0.43–1.53] 0.525
∧
Time to respiratory rate < 24 bpm 5.00 (2.00–9.00) 5.00 (3.00–7.00) 1.03 (0.59–1.81) 0.909∧
Patients who achieved clinical stability
at day 10 11 (40.7%) 11 (39.3%) 1.06 [0.35–3.19] 0.915*
at day 28 18 (66.7%) 21 (75.0%) 0.67 [0.20–2.21] 0.515*
at day 56 21 (77.8%) 22 (78.6%) 0.96 [0.25–3.61] 0.946*
Time to an eight-point ordinal scale ≤ 3 12.5 (8.00–15.2) 15.0 (9.00–24.0) 0.92 [0.49–1.71] 0.787∧
Patients who reach an eight-point ordinal scale ≤ 3
at day 10 9 (33.3%) 7 (25.0%) 1.48 [0.45–5.03] 0.515*
at day 28 18 (66.7%) 20 (71.4%) 0.80 [0.25–2.59] 0.714*
at day 56 20 (74.1%) 21 (75.0%) 0.95 [0.27–3.33] 0.940*
Discharge at day 56 21 (77.8%) 21 (75.0%) 1.16 [0.32–4.28] 0.819*
Duration of hospital stay, days 13.0 (8.50–21.0) 14.0 (9.00–22.5) .. 0.933**
COVID-19-related mortality
at day 10 2 (7.41%) 3 (10.7%) 0.69 [0.07–4.88] 0.705*
at day 28 3 (11.1%) 4 (14.3%) 0.76 [0.13–4.02] 0.747*
at day 56 4 (14.8%) 4 (14.3%) 1.04 [0.21–5.13] 0.958*
Time from randomization to COVID-19-related death, days 18.0 (9.50–27.8) 7.00 (3.50–12.5) 0.96 [0.24–3.84] 0.953∧
All-cause mortality
at day 10 2 (7.41%) 5 (17.9%) 0.39 [0.05–2.10] 0.282*
at day 28 4 (14.8%) 6 (21.4%) 0.65 [0.14–2.67] 0.551*
at day 56 5 (18.5%) 6 (21.4%) 0.84 [0.21–3.28] 0.800*
Time from randomization to all-cause death, days 13.0 (10.0–26.0) 7.00 (3.25–10.0) 0.80 [0.24–2.61] 0.707∧
Data are median (IQR) or n (%). COVID-19, Coronavirus disease 2019; FiO2, fractional inspired oxygen; OS, ordinal scale; PaO2, arterial oxygen partial pressure; SpO2, oxygen saturation.
Clinical stability (the event) was defined as fulfilling all of the following criteria for 48 consecutive hours: body temperature ≤ 37.5◦C; PaO2/FiO2 > 400 and/or SpO2/FiO2 > 300; and
respiratory rate ≤ 24 breaths per minute (bpm). Treatment failure was defined as: (1) patient who does not meet the criteria for clinical stability 56 days after starting treatment; (2) patient
presenting a serious adverse event attributed to trial treatment; or (3) patient who dies after being included in the clinical trial. Differences are expressed as ∧ Hazard Ratio [CI 95%] and
p-value; *Odds ratio [CI 95%] and p-value; ** Wilcoxon test and p-value.
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FIGURE 2 | Time to clinical stability in the intention-to-treat population.
FIGURE 3 | All cause mortality in the ITT population.
hospitalized patients with severe COVID-19. Furthermore,
no differences were observed in the clearance of the
virus or in the rate of adverse events between the
two groups.
The TACROVID trial was initiated in March 29, 2020
when there were no medical reports supporting the use
of immunosuppressive therapy in severe COVID-19.
Nonetheless, all of the trial’s patients received corticosteroids.
Methylprednisolone and tacrolimus lead to impaired lymphocyte
function (7, 13) and therefore it could facilitate SARS-CoV-
2 replication and also promote the development of other
infections. On the other hand, CNIs have been shown to
inhibit the growth of human coronaviruses at low micromolar,
non-cytotoxic concentrations in cell cultures by immunophilin
pathway inhibition (16, 17). Based on this finding, it has been
suggested that CNIs could be used as an antiviral agent to
treat COVID-19. However, we would like to highlight that the
concentrations used in cell culture are not clinically achievable,
as they correspond to highly toxic blood levels in humans
(24). Accordingly, the proposed use of tacrolimus should be
restricted to the inflammatory stages of COVID-19. In this trial,
tacrolimus had no significant effect on SARS-CoV-2 RNA loads
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either in the upper respiratory tract or in blood specimens in
our patients.
The ratio of most treatments (antibiotics, lopinavir-ritonavir,
hydroxychloquine, heparin, and tocilizumab) used was similar
in the two groups. Interestingly, the largest and longest
corticosteroids doses were used in the control group, although
we do not know the exact reasons. During follow up both
groups had similar laboratory test results, needed similar
rates of high-flow and ventilation devices, and developed
similar CXR parenchymal involvement. Notably, those patients
receiving the experimental therapy had a numerically shorter
time to achieve an eight-point ordinal scale ≤ 3 than those
receiving SoC within 10 days of randomization, although
this trend was later reversed. Finally, this was an open-label
trial and the control group patients who could not receive
tacrolimus may have received more corticosteroids or other
immunosuppressants (anakinra).
Although not statistically significant, patients receiving the
experimental therapy had numerically lower all-cause mortality
than those receiving SoC, especially during the first 28 days.
This data supports non-randomized studies that showed that
cyclosporine could reduce mortality, mainly in patients with
moderate to severe COVID-19 (19, 20). Interestingly, tacrolimus
use had a positive independent effect on survival vs. all
other immunosuppressant (cyclosporine, mycophenolate and/or
mTOR inhibitors) according to a multi-center European study
carried out on 243 adult liver transplant recipients with
symptomatic COVID-19, suggesting that it could be even more
beneficial than cyclosporine (25). The mortality data from
days 28 to 56 of the trial are less valuable because only five
patients were still admitted to the hospital in the experimental
group (Supplementary Table 7), and experimental therapy was
withdrawn previously in all of them due to mechanical invasive
ventilation or serious AE.
Likewise, there was no difference in adverse events overall
between groups. Patients in the experimental group seemed to
have a slightly higher number of non-serious and serious AE
infections. We also have to consider that corticosteroids have
been associated with gastrointestinal bleeding, hyperglycaemia,
and neuromuscular weakness (26). In fact, the group treated with
tacrolimus received a significantly lower dose of corticosteroids,
having better control of glucose metabolism and a lower rate
of bleeding.
However, the trial had some limitations. First, the current
trial was not conducted as a double-blind trial. This was
considered unrealistic given the intense workload experienced
at the beginning of the pandemic in our local setting. To
minimize the impact of an open-label design, the statistician
performing the analysis was blinded to the trial arm. Second,
the TACROVID trial had a limited sample size and clearly
was not sufficiently powered to detect a difference in time to
clinical stability and mortality between the two groups after
the early termination that occurred with 29 (34.1%) patients
fewer than expected. Furthermore, the limited sample size caused
certain imbalances in the baseline characteristics between the
two groups after randomization. Third, all included patients
received corticosteroids, heparins, and hydroxychloroquine; and
most (89.1%) of them also received tocilizumab as part of the
SoC. In this respect, the additional use of any other medication
regimens (except for cyclosporine) in both arms, as part of
the SoC, limits the assessment of which was the real effect
of each drug on clinical outcomes, laboratory data and the
occurrence of AE. Moreover, tacrolimus strongly interacts with
some treatments (especially lopinavir) used at that time in
COVID-19. Most (85.2%) patients in the experimental group
received concomitant treatment with lopinavir-ritonavir, as it
was extremely difficult to achieve the recommended plasma
levels of tacrolimus. Finally, the lack of medical evidence
supporting immunosuppressive therapies in COVID-19, when
the trial was conducted, made us more cautious, withdrawing
experimental therapy when mechanical invasive ventilation
was implemented. Therefore, its efficacy and safety cannot
be assessed by this trial in this subset of patients with life-
threatening COVID-19.
In summary, the combined use of methylprednisolone pulses
and tacrolimus, in addition to the SoC did not significantly
improve the time to clinical stability or other secondary
outcomes compared with SoC alone in hospitalized patients
with severe COVID-19. Although not statistically significant,
patients receiving the experimental therapy had numerically
lower all-cause mortality than those receiving SoC. No relevant
differences were observed in the clearance of the virus or in
the rate of adverse events between the two groups. The reason
why the largest and longest corticosteroid doses were used
in the control group remains unclear. It is noteworthy that
the present trial had a limited sample size and several other
limitations. Therefore, further RCTs should be done to assess the
efficacy and safety of tacrolimus to tackle the inflammatory stages
of COVID-19.
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